To Minh D, Wong Christine E, Karnezis Anthony N, Del Rosario Reyno, Di Lauro Roberto, Balmain Allan
University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, Cancer Research Institute, San Francisco, California 94115, USA.
Nat Genet. 2008 Oct;40(10):1240-4. doi: 10.1038/ng.211. Epub 2008 Aug 31.
Kras is the most frequently mutated ras family member in lung carcinomas, whereas Hras mutations are common in tumors from stratified epithelia such as the skin. Using a Hras knock-in mouse model, we demonstrate that specificity for Kras mutations in lung and Hras mutations in skin tumors is determined by local regulatory elements in the target ras genes. Although the Kras 4A isoform is dispensable for mouse development, it is the most important isoform for lung carcinogenesis in vivo and for the inhibitory effect of wild-type (WT) Kras on the mutant allele. Kras 4A expression is detected in a subpopulation of normal lung epithelial cells, but at very low levels in lung tumors, suggesting that it may not be required for tumor progression. The two Kras isoforms undergo different post-translational modifications; therefore, these findings can have implications for the design of therapeutic strategies for inhibiting oncogenic Kras activity in human cancers.
Kras是肺癌中最常发生突变的ras家族成员,而Hras突变在皮肤等复层上皮来源的肿瘤中较为常见。利用Hras基因敲入小鼠模型,我们证明了肺癌中Kras突变和皮肤肿瘤中Hras突变的特异性是由目标ras基因中的局部调控元件决定的。尽管Kras 4A异构体对小鼠发育并非必需,但它是体内肺癌发生以及野生型(WT)Kras对突变等位基因抑制作用中最重要的异构体。在正常肺上皮细胞亚群中可检测到Kras 4A表达,但在肺肿瘤中的表达水平非常低,这表明它可能不是肿瘤进展所必需的。两种Kras异构体经历不同的翻译后修饰;因此,这些发现可能对设计抑制人类癌症中致癌性Kras活性的治疗策略具有启示意义。